The impact of medicare part D on medication adherence among older adults enrolled in medicare-advantage products

Medical Care

Volumn 48, Issue 5, 2010, Pages 409-417

  Zhang, Yuting ^a   Lave, Judith R ^a   Donohue, Julie M ^a   Fischer, Michael A ^b   Chernew, Michael E ^c   Newhouse, Joseph P ^c,d,e  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

Medicare Part D; Medication adherence; Pharmacy benefit design

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

AGED; ARTICLE; CHRONIC DISEASE; DIABETES MELLITUS; DRUG COST; FEMALE; GERIATRIC PATIENT; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSURANCE CLAIM REVIEW; MALE; MEDICARE PART D; MEDICATION ADHERENCE; SEX FACTORS; UNITED STATES;

EID: 77951620905     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181d68978     Document Type: Article

References (48)

1. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff. 2005;(suppl web exclusives):W5-152-W5-166.
2. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42:626-634.
3. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354:2349-2359.
4. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor elderly persons. JAMA. 2001;285:421-429
5. SHEP Cooperative Research Group. Prevention of stroke by antihyper-tensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
7. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.
8. Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003;6:566-573.
9. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
10. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008;17:1189-1196.
11. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165:1147-1152.
12. Zhang Y, Donohue JM, Lave JR, et al. The impact of the Medicare Part D drug benefits on pharmacy and medical care spending. N Engl J Med. 2009;361:52-61.
13. Zhang Y, Lave JR, Newhouse JP, et al. How the Medicare Part D Drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. J Gerontol B Psychol Sci Soc Sci. 2009 Dec 14. [Epub ahead of print.]
14. Ketcham JD, Simon KI. Medicare Part D's effects on elderly patients' drug costs and utilization. Am J Manag Care. 2008;14:SP14-SP22.
15. Yin W, Basu A, Zhang JX, et al. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008;148:169-177.
16. Lichtenberg FR, Sun SX. The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood). 2007;26: 1735-1744.
17. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication non-adherence and spending on basic needs following implementation of Medicare Part D. JAMA. 2008;299:1922-1928.
18. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2004. Available at: http://www.nhlbi.nih.gov/ guidelines/cholesterol/index.htm. Accessed July 30, 2009
19. National Heart Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Heart Lung and Blood Institute; 2003.
20. American Diabetes Association. Executive summary: standards of medical care in diabetics. Diabetes Care. 2008;31:S5-S11.
21. Centers for Medicare & Medicaid Services. Medicare prescription drug benefit symposium: Part D data symposium fact sheet. 2008. Available at: http://www.cms.hhs.gov/prescriptiondrugcovgenin/08-partddata.asp. Accessed March 10, 2009
22. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
23. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ. 2003;326:1427-1435.
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hypergly-cemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
25. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386-399.
26. Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcome Res Meth. 2001;2:259-278.
27. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163:262-270.
28. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14:680-686.
29. Li F, Zaslavsky AM, Landrum MB. Propensity score analysis with hierarchical data. In: Proceedings of the American Statistical Association Joint Statistical Meetings; July 29-August 2, 2007; Salt Lake City, UT.
30. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev. 2004;25:119-141.
31. Kang Joseph DY, Schafer JL. Demystifying double robustness: a comparison of alternative strategies for estimating a population mean from incomplete data. Stat Sci. 2007;22:523-539.
32. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049-1060.
33. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
34. Afifi AA, Kotlerman JB, Ettner SL, et al. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health. 2007;28:95-111.
35. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005;6:93-109.
36. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17: 247-281.
37. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24:465-488.
38. Greene WH. Econometric Analysis. Upper Saddle River, NJ: Prentice Hall; 2003.
39. Goldman DP, Joyce GE, Escarce J, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-2350.
40. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
41. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copay-ments on medication adherence within a disease management environment. Health Aff. 2008;27:103-112.
42. Newhouse JP. Free for all?: Lessons From the RAND Health Insurance Experiment. Cambridge, MA: Harvard University Press; 1993.
43. Schneeweiss S, Patrick AR, Pedan A, et al. The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff (Millwood). 2009;28:w305-w316.
44. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and application. J Clin Epidemiol. 1997;50:105-116.
45. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261: 3273-3277.
46. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26:w195-w203.
47. Choudhry NK, Avorn J, Antman EM, et al. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff. 2007;26:186-194.
48. Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117: 1261-1268.